NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study

Abstract

Objective:

To establish the optimal safe dose of everolimus in combination with ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy (PRRT) of advanced progressive gastro-entero pancreatic neuroendocrine tumors (GEP-NETs) and to define dose-limiting toxicity.

Patients and Methods:

Patients with advanced unresectable progressive well-differentiated GEP-NETS avid for ⁶⁸Ga-octreotate on positron emission tomography–computed tomography imaging underwent PRRT with four cycles of 7.8 GBq ¹⁷⁷Lu-octreotate at 8 week intervals. Successive cohorts of 3 patients received escalating doses of everolimus comprising 5, 7.5, and 10 mg daily for 24 weeks.

Results:

Sixteen patients comprised 4 at 5 mg, 9 at 7.5 mg, and 3 at 10 mg everolimus. Patient cohorts at 5 and 7.5 mg received 83% and 80% of the total planned dose of everolimus over 24 weeks. All patients required dose reduction or complete cessation of everolimus at the 10 mg level, which induced neutropenia and thrombocytopenia, and reduced creatinine clearance. The overall response rate was 44% (7 of 16 patients), and no patient progressed over the 6 month period of treatment. Four of 5 pancreatic NET patients achieved PR 80%. No patient progressed on study.

Conclusion:

In combination, PRRT with ¹⁷⁷Lu-octreotate, the maximum tolerated dose of everolimus is 7.5 mg daily.